How I treat MDS after hypomethylating agent failure.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2018-03-785915
Abstract: Hypomethylating agents (HMA) azacitidine and decitabine are standard of care for myelodysplastic syndrome (MDS). Response to these agents occurs in ∼50% of treated patients, and duration of response, although variable, is transient. Prediction of response… read more here.
Keywords: hypomethylating agent; hma failure; treat mds; mds hypomethylating ... See more keywords